1
|
Stenirri S, Battistella S, Soriani N, Bernal S, Baiget M, Ferrari M, Cremonesi L. Molecular Scanning of the ABCA4 Gene in Spanish Patients with Retinitis Pigmentosa and Stargardt Disease: Identification of Novel Mutations. Eur J Ophthalmol 2018; 17:749-54. [DOI: 10.1177/112067210701700510] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- S. Stenirri
- Genomic Unit for Diagnosis of Human Pathologies, San Raffaele Scientific Institute, Milano - Italy
| | - S. Battistella
- Genomic Unit for Diagnosis of Human Pathologies, San Raffaele Scientific Institute, Milano - Italy
| | - N. Soriani
- Genomic Unit for Diagnosis of Human Pathologies, San Raffaele Scientific Institute, Milano - Italy
| | - S. Bernal
- Servei de Genètica, Hospital Sant Pau, Barcelona - Spain
| | - M. Baiget
- Servei de Genètica, Hospital Sant Pau, Barcelona - Spain
| | - M. Ferrari
- Genomic Unit for Diagnosis of Human Pathologies, San Raffaele Scientific Institute, Milano - Italy
- Diagnostica e Ricerca San Raffaele SpA, Milano
- Università Vita-Salute San Raffaele, Milano - Italy
| | - L. Cremonesi
- Genomic Unit for Diagnosis of Human Pathologies, San Raffaele Scientific Institute, Milano - Italy
| |
Collapse
|
2
|
Gallano P, Gonzalez-Quereda L, Lasa A, Baena M, Rodriguez M, Monges S, Lubieniecki F, Nascimento A, Ortez C, Baiget M. Dystrophinopathies: A NGS approach for the molecular analysis of DMD gene. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
3
|
Arqueros C, Paez D, Salazar J, Del Rio E, Arranz M, Mora J, Sullivan I, Tobeña M, Martín Richard M, Sebio A, Baiget M. 205 SPARC gene variants predict survival of locally advanced and metastatic pancreatic cancer patients treated with chemotherapy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30093-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Sebio A, Salazar J, Páez D, Berenguer-Llergo A, del Río E, Tobeña M, Martín-Richard M, Sullivan I, Targarona E, Balart J, Baiget M, Barnadas A. EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer. Pharmacogenomics J 2014; 15:77-83. [DOI: 10.1038/tpj.2014.33] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Revised: 03/31/2014] [Accepted: 05/22/2014] [Indexed: 02/06/2023]
|
5
|
Fernandez-Rozadilla C, Cazier JB, Tomlinson I, Brea-Fernández A, Lamas MJ, Baiget M, López-Fernández LA, Clofent J, Bujanda L, Gonzalez D, de Castro L, Hemminki K, Bessa X, Andreu M, Jover R, Xicola R, Llor X, Moreno V, Castells A, Castellví-Bel S, Carracedo A, Ruiz-Ponte C. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer. Hum Genet 2014; 133:525-34. [PMID: 24218287 DOI: 10.1007/s00439-013-1390-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Accepted: 10/24/2013] [Indexed: 11/30/2022]
Abstract
Colorectal cancer (CRC) is a complex disease, and therefore its development is determined by the combination of both environmental factors and genetic variants. Although genome-wide association studies (GWAS) of SNP variation have conveniently identified 20 genetic variants so far, a significant proportion of the observed heritability is yet to be explained. Common copy-number variants (CNVs) are one of the most important genomic sources of variability, and hence a potential source to explain part of this missing genetic fraction. Therefore, we have performed a GWAS on CNVs to explore the relationship between common structural variation and CRC development. Phase 1 of the GWAS consisted of 881 cases and 667 controls from a Spanish cohort. Copy-number status was validated by quantitative PCR for each of those common CNVs potentially associated with CRC in phase I. Subsequently, SNPs were chosen as proxies for the validated CNVs for phase II replication (1,342 Spanish cases and 1,874 Spanish controls). Four common CNVs were found to be associated with CRC and were further replicated in Phase II. Finally, we found that SNP rs1944682, tagging a 11q11 CNV, was nominally associated with CRC susceptibility (p value = 0.039; OR = 1.122). This locus has been previously related to extreme obesity phenotypes, which could suggest a relationship between body weight and CRC susceptibility.
Collapse
Affiliation(s)
- C Fernandez-Rozadilla
- Fundación Pública Galega de Medicina Xenómica (FPGMX)-SERGAS, Grupo de Medicina Xenómica, IDIS, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERer), Complexo Hospitalario Universitario de Santiago, Choupana s/n, 15706, Santiago, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Álvarez-Satta M, Castro-Sánchez S, Pereiro I, Piñeiro-Gallego T, Baiget M, Ayuso C, Valverde D. Overview of Bardet-Biedl syndrome in Spain: identification of novel mutations in BBS1, BBS10 and BBS12 genes. Clin Genet 2014; 86:601-2. [PMID: 24611592 DOI: 10.1111/cge.12334] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Revised: 12/13/2013] [Accepted: 12/17/2013] [Indexed: 11/27/2022]
Affiliation(s)
- M Álvarez-Satta
- Departamento de Bioquímica, Genética e Inmunología, Facultad de Biología, Universidad de Vigo, Vigo, Spain
| | | | | | | | | | | | | |
Collapse
|
7
|
Juan-Mateu J, González-Quereda L, Rodriguez M, Jou C, Nascimento A, Jimenez-Mallebrera C, Colomer J, Baiget M, Olive M, Gallano P. P.2.14 Isolated cognitive abnormalities associated to DMD mutations. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.419] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Alías L, Barceló M, Bernal S, Martínez-Hernández R, Also-Rallo E, Vázquez C, Santana A, Millán J, Baiget M, Tizzano E. Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of theSMN1gene. Clin Genet 2013; 85:470-5. [DOI: 10.1111/cge.12222] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Revised: 06/21/2013] [Accepted: 06/21/2013] [Indexed: 11/27/2022]
Affiliation(s)
- L. Alías
- Servicio de Genética; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
- CIBERER (U705); Barcelona Spain
| | - M.J. Barceló
- Servicio de Genética; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
- CIBERER (U705); Barcelona Spain
| | - S. Bernal
- Servicio de Genética; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
- CIBERER (U705); Barcelona Spain
| | - R. Martínez-Hernández
- Servicio de Genética; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
- CIBERER (U705); Barcelona Spain
| | - E. Also-Rallo
- Servicio de Genética; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
- CIBERER (U705); Barcelona Spain
| | - C. Vázquez
- Clinical Genetics Unit; Hospital Materno Infantil de Las Palmas; Gran Canaria Spain
| | - A. Santana
- Clinical Genetics Unit; Hospital Materno Infantil de Las Palmas; Gran Canaria Spain
- CIBERER (U740); La Laguna, Tenerife Spain
- Research Unit; Hospital Dr Negrin de Las Palmas; Gran Canaria Spain
| | - J.M. Millán
- Hospital La Fe; Valencia Spain
- CIBERER (U755); Valencia Spain
| | - M. Baiget
- Servicio de Genética; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
- CIBERER (U705); Barcelona Spain
| | - E.F. Tizzano
- Servicio de Genética; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
- CIBERER (U705); Barcelona Spain
| |
Collapse
|
9
|
Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guinó E, Durán G, Lamas MJ, López R, Candamio S, Gallardo E, Paré L, Baiget M, Páez D, López-Fernández LA, Cortejoso L, García MI, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé JM, Jover R, Brea-Fernández A, Andreu M, Bessa X, Llor X, Xicola R, Palles C, Tomlinson I, Castellví-Bel S, Castells A, Ruiz-Ponte C, Carracedo A. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J 2013; 13:209-17. [PMID: 22310351 DOI: 10.1038/tpj.2012.2] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Revised: 12/13/2011] [Accepted: 01/03/2012] [Indexed: 02/04/2023]
Abstract
The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale.
Collapse
Affiliation(s)
- C Fernandez-Rozadilla
- Galician Public Foundation of Genomic Medicine-FPGMX-Centro de Investigación Biomédica en Red de Enfermedades Raras-CIBERER-Genomics Medicine Group-Hospital Clínico Santiago de Compostela-University of Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Moya P, Salazar J, Altés A, Corominas H, Diaz-Torne C, Castellví I, Geli C, Córica ME, del Rio E, de Llobet JM, Baiget M. AB0189 Polymorphisms in genes involved in the metotrexate action mechanism. are they associated with response/toxicity of the drug? Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
Juan-Mateu J, Fernandez M, Gonzalez-Quereda L, Verdura E, Colomer A, Nascimento A, Baiget M, Gallano P. G.P.79 DMD mutation spectrum in 611 unrelated dystrophinopathy families. Neuromuscul Disord 2012. [DOI: 10.1016/j.nmd.2012.06.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Sullivan I, Majem Tarruella M, Páez D, Pallarés C, Paré L, Del Rio E, Lopez Pousa A, Barnadas A, Ramón Y Cajal T, Baiget M. Effect of Germline Polymorphisms of DNA Repair Genes on Chemotherapy Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33837-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
13
|
Murata E, Stradella A, Páez D, Puyal MT, Garcia AS, Gonzalez A, Targarona E, Baiget M, Barnadas A, Martín-Richard M. Prognostic Value of BRAF and KRAS Mutations in Colorectal Cancer Patients. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33113-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
14
|
Venceslá Á, Baena M, Garrido RP, Núñez R, Velasco F, Rosell J, Villar A, Jiménez-Yuste V, Baiget M, Tizzano EF. F8 gene dosage defects in atypical patients with severe haemophilia A. Haemophilia 2012; 18:708-13. [PMID: 22621702 DOI: 10.1111/j.1365-2516.2012.02818.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We performed molecular analysis of the factor 8 gene (F8) in 272 unrelated Spanish patients with haemophilia A (HA) and detected a mutation by routine analysis in 267 of them (98.1%). No mutation was detected in the remaining five patients despite clinical and laboratory confirmation of HA. The aim is to describe the molecular alterations in F8 discovered by gene dosage methodologies in three of these patients. For methodology, F8 sequencing, intragenic marker analysis, multiplex ligation-dependent probe amplification and quantitative real time-PCR were followed. One patient had Klinefelter syndrome (47,XXY) and a large deletion spanning exons 1-12 masked by the other F8 allele; the second patient showed a large duplication spanning exons 2-10 and the third patient revealed a non-contiguous double duplication of exons 14 and 23-25. The remaining two patients had mild HA and dosage results were normal. The application of gene dosage methods is useful to define haemophilic patients in whom mutations are not detected using other routine methods. Nevertheless, in a small percentage of patients (<1%), no molecular pathology can be identified after testing several genetic methodologies.
Collapse
Affiliation(s)
- Á Venceslá
- Department of Genetics, Hospital de Sant Pau, Barcelona and CIBERER U-705, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Juan-Mateu J, Paradas C, Olivé M, Verdura E, Rivas E, González-Quereda L, Rodríguez MJ, Baiget M, Gallano P. Isolated cardiomyopathy caused by a DMD nonsense mutation in somatic mosaicism: genetic normalization in skeletal muscle. Clin Genet 2011; 82:574-8. [PMID: 22092019 DOI: 10.1111/j.1399-0004.2011.01814.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
X-linked dilated cardiomyopathy is a pure cardiac dystrophinopathy phenotype mainly caused by DMD mutations that present a specific transcription effect in cardiac tissue. We report a 26-year-old male who presented with severe dilated cardiomyopathy and high creatine kinase. The patient did not complain of skeletal muscle weakness. A muscle biopsy showed mild dystrophic changes and a low proportion of dystrophin-negative fibres. A molecular study identified a nonsense DMD mutation (p.Arg2098X) in somatic mosaicism. The ratio of mutant versus normal allele in blood and skeletal muscle suggests selective pressure against mutant muscle cells, a process known as genetic normalization. We hypothesize that this process may have mitigated skeletal muscle symptoms in this patient. This is the second report of a DMD somatic mosaic with evidence of genetic normalization in muscle. Somatic DMD mutations should be considered in patients presenting with idiopathic dilated cardiomyopathy.
Collapse
Affiliation(s)
- J Juan-Mateu
- Genetics Department, Hospital Sant Pau, CIBERER, Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Gonzalez-Quereda L, Delgadillo V, Juan-Mateu J, Verdura E, Rodriguez M, Baiget M, Pineda M, Gallano P. LMNA mutation in progeroid syndrome in association with strokes. Eur J Med Genet 2011; 54:e576-9. [DOI: 10.1016/j.ejmg.2011.06.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2011] [Accepted: 06/28/2011] [Indexed: 01/18/2023]
|
17
|
Verdura E, Gonzalez-Quereda L, Juan-Mateu J, Rodriguez M, Cabello A, Castro Gago M, Coll J, Colomer J, Gutierrez-Rivas E, Hankiewicz K, Lopez de Munain A, Navarro C, Pascual S, Pou A, Ramos M, Vidal Ríos P, Baiget M, Gallano P. P2.34 Mutational spectrum of sarcoglycanopathies in Spain. Neuromuscul Disord 2011. [DOI: 10.1016/j.nmd.2011.06.856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
18
|
Juan-Mateu J, Verdura E, Rodriguez M, Gonzalez-Quereda L, Colomer J, Díaz-Manera J, Gallardo E, Gonzalez-Mera L, Macaya A, Munell F, Nascimento A, Navarro C, Olive M, Pascual J, Pou A, Rivas E, Roig M, Baiget M, Gallano P, Madruga M, Jimenez-Mallebrera C. P1.18 Dystrophinopathy in manifesting female carriers: Clinical and genetic characterization in a cohort of 20 patients. Neuromuscul Disord 2011. [DOI: 10.1016/j.nmd.2011.06.778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
19
|
Sebio A, Paez D, Pare L, Salazar J, Del Rio E, Barnadas A, Baiget M. A pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy based on capecitabine: Polymorphisms in thymidilyate synthase and DNA repair genes. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Cocho D, Martí-Fàbregas J, Baiget M, Gallardo E, Rio E, Arboix A, Ruscalleda J, Martí-Vilalta JL. Diagnosis of CADASIL disease in normotensive and non-diabetics with lacunar infarct. Neurologia 2011; 26:325-30. [PMID: 21345538 DOI: 10.1016/j.nrl.2010.12.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2010] [Revised: 11/09/2010] [Accepted: 12/01/2010] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is characterized by recurrent cerebral ischemic episodes of the lacunar subtype usually without traditional vascular risk factors. We investigated the frequency of CADASIL among selected patients with cerebral ischemia of the lacunar subtype. METHODS we studied patients under 65 years old who presented cerebral ischemia of the lacunar subtype without hypertension, diabetes mellitus or other causes that explained the cerebral ischemia. On the skin biopsies, we performed immunostaining analysis on 5μm frozen sections with monoclonal antibody anti-Notch 3 (1E4). We also performed a genetic analysis of the Notch 3 gene (exons 3,4,5,6,11 and 19). RESULTS of 1.519 patients analyzed, only 57 (3.7%) fulfilled the selection criteria, and 30 of them accepted to participated in the study. We studied 30 patients, mean age was 53 years (range 34 to 65), 50% were men and all patients suffered a lacunar stroke. Immunostaining analysis was positive in two patients (6.6%) and the genetic analysis confirmed a mutation characteristic of CADASIL in exon 4 nt 622C/T (Arg 182 Cys) and 694 T/C (Cys206Arg) respectively. CONCLUSIONS CADASIL disease was present in 6.6% of patients younger than 65 years with a lacunar stroke and without hypertension or diabetes mellitus. Screening for CADASIL should be considered in these patients.
Collapse
Affiliation(s)
- D Cocho
- Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Cocho D, Martí-Fàbregas J, Baiget M, Gallardo E, Rio E, Arboix A, Ruscalleda J, Martí-Vilalta J. Diagnosis of CADASIL disease in normotensive and non-diabetics with lacunar infarct. Neurología (English Edition) 2011. [DOI: 10.1016/s2173-5808(11)70077-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
22
|
Parra J, Martinez-Hernandez R, Barcelo M, Alı´as L, Also-Rallo E, Amenedo M, Calaf J, Baiget M, Bernal S, Gallano P, Tizzano E. P3.34 Ultrasound evaluation of nuchal translucency thickness and fetal movements in 98 pregnancies at risk for type I spinal muscular atrophy: relevance of the SMN2 copy number. Neuromuscul Disord 2010. [DOI: 10.1016/j.nmd.2010.07.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Gesteira A, Barros F, Martín A, Pérez V, Cortés A, Baiget M, Carracedo A. Pharmacogenetic studies on the antipsychotic treatment. Current status and perspectives. Actas Esp Psiquiatr 2010; 38:301-316. [PMID: 21117005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/01/2010] [Accepted: 09/01/2010] [Indexed: 05/30/2023]
Abstract
Based on present knowledge, in this work we review the importance of the pharmacogenetic tests in the treatment with antipsychotic drugs. Many associations have been reported between different genetic markers and response to treatment as well as to the appearance of adverse reactions. However, up to now, no "prime" biomarker capable of unequivocally predicting the clinical benefits of a specific treatment or its toxicity has been identified. The use of individual pharmacogenetic markers has been demonstrated to have little clinical utility, and therefore the combination of information obtained from the analysis of different genes seems to be a more promising strategy. Inclusion of pharmacogenetic tests in clinical trials conducted prospectively and that include a large number of cases could, undoubtedly, significantly contribute to the development of individualized medicine protocols.
Collapse
Affiliation(s)
- A Gesteira
- Unidad de Medicina Molecular, Hospital Clínico Universitario, C/Choupana s/n 15706 Santiago de Compostela.
| | | | | | | | | | | | | |
Collapse
|
24
|
Bernal S, Alías L, Barceló MJ, Also-Rallo E, Martínez-Hernández R, Gámez J, Guillén-Navarro E, Rosell J, Hernando I, Rodríguez-Alvarez FJ, Borrego S, Millán JM, Hernández-Chico C, Baiget M, Fuentes-Prior P, Tizzano EF. The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. J Med Genet 2010; 47:640-2. [PMID: 20577007 DOI: 10.1136/jmg.2010.079004] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Homozygous mutations of the telomeric SMN1 gene lead to degeneration of motor neurons causing spinal muscular atrophy (SMA). A highly similar centromeric gene (SMN2) can only partially compensate for SMN1 deficiency. The c.859G>C variant in SMN2 has been recently reported as a positive disease modifier. We identified the variant in 10 unrelated chronic SMA patients with a wide spectrum of phenotypes ranging from type II patients who can only sit to adult walkers. Haplotype analysis strongly suggests that the variant originated from a common ancestor. Our results confirm that the c.859G>C variant is a milder SMN2 allele and predict a direct correlation between SMN activity and phenotypic severity.
Collapse
|
25
|
Lasa A, Ramón y Cajal T, Llort G, Suela J, Cigudosa JC, Cornet M, Alonso C, Barnadas A, Baiget M. Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation. Breast Cancer Res Treat 2010; 123:901-5. [DOI: 10.1007/s10549-010-0877-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2010] [Accepted: 03/25/2010] [Indexed: 01/09/2023]
|
26
|
Paez D, Espinosa I, Altés A, del Rio E, Salazar J, Barnadas A, Marcuello E, Baiget M. 6108 Association of FcGammaRIIa-FcGammaRIIIa polymorphisms and KRAS mutations with clinical outcome in advanced colorectal cancer patients treated with antiEGFR based treatment. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71203-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
27
|
Ramón y Cajal T, Altés A, Paré L, del Rio E, Alonso C, Barnadas A, Baiget M. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2009; 119:33-8. [PMID: 19189210 DOI: 10.1007/s10549-009-0328-y] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2008] [Accepted: 01/20/2009] [Indexed: 10/21/2022]
Abstract
The aim of this study is to evaluate the impact of CYP2D6 genotyping in predicting disease-free survival and toxicity in breast cancer patients treated with adjuvant tamoxifen. DNA from 91 patients was genotyped using the AmpliChip CYP450 GeneChip, Roche that facilitates the classification of individuals by testing 27 alleles. When patients were grouped into group 1 (*4/*4, *4/*41, *1/*5 and *2/*5) and group 2 (the remaining genotypes), a significant difference in disease-free survival (DFS) was observed between groups (P = 0.016). The mean DFS in group 1 was 95 months in contrast with 119 months in group 2. No significant relationship was found between the CYP2D6 genotype classification and severe, mild or no toxicity (P = 0.2). Nevertheless, severe, and mild toxicity was more frequent among poor metabolizer patients than in patients with a normal metabolizer pattern (18.8 and 43.8% vs. 10.7 and 36%, respectively). In breast cancer, patients treated with adjuvant tamoxifen, non-functional and severely impaired CYP2D6 variants are associated with a worse DFS and with a higher frequency of severe and mild toxicities. Larger studies of the CYP2D6 genotype-clinical outcomes association are needed to complement initial results.
Collapse
Affiliation(s)
- T Ramón y Cajal
- Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
28
|
Venceslá A, Fuentes-Prior P, Baena M, Quintana M, Baiget M, Tizzano EF. Severe haemophilia A in a female resulting from an inherited gross deletion and a de novo codon deletion in the F8 gene. Haemophilia 2008; 14:1094-8. [PMID: 18665854 DOI: 10.1111/j.1365-2516.2008.01816.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Haemophillia A (HA) is an X-linked bleeding disorder caused by mutations in the F8 gene. While the disease affects 1 in 5000 males, phenotypic expression of haemophilia A is rare in females, similar to other X-linked recessive disorders. We describe a 5-year-old female with severe haemophilia A. We determined the underlying molecular defect in the F8 genes of the proband and her closest family members by direct DNA sequencing, marker analysis and quantitative real-time polymerase chain reaction. The patient showed two different mutations in the F8 gene: the paternal copy of the F8 gene had a de novo p.Phe652/653 deletion in exon 13 while the maternally inherited gene showed a large deletion encompassing exons 1 to 22. The structural analysis of residues Phe652/Phe653 based on a three-dimensional model of activated factor VIII provides evidence of the impact of the mutant factor VIII protein in the clinical manifestations of the patient. This unusual finding highlights the need to perform a thorough molecular analysis including sequencing, marker and quantitative analyses to identify compound heterozygous females with HA.
Collapse
Affiliation(s)
- A Venceslá
- Department of Genetics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
29
|
Páez López-Bravo D, Altés A, Sancho-Poch FJ, Garriga J, Petriz M, Pare L, del Río E, Barnadas Molins A, Baiget M, Marcuello E. Pharmacogenetic studies in rectal cancer patients treated with preoperative chemoradiotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Marcuello E, Paré L, Páez López-Bravo D, del Río E, Barnadas Molins A, Altés A, Baiget M. A genotype-based dose-escalation study of irinotecan in advanced colorectal cancer patients treated in second-line of chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14599] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Pare L, del Río E, López-Bravo DP, Baiget M. Genetic variation and haplotype structures of the gene encoding human thymidylate synthase, a pharmacogenetic marker in fluoropyrimidine-treated cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Bernal S, Solans T, Gamundi MJ, Hernan I, De Jorge L, Carballo M, Navarro R, Tizzano E, Ayuso C, Baiget M. Analysis of the involvement of the NR2E3 gene in autosomal recessive retinal dystrophies. Clin Genet 2008; 73:360-6. [DOI: 10.1111/j.1399-0004.2008.00963.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Pascual JC, Soler J, Baiget M, Cortés A, Menoyo A, Barrachina J, Ropero M, Gomà M, Alvarez E, Perez V. Association between the serotonin transporter gene and personality traits in borderline personality disorder patients evaluated with Zuckerman-Zuhlman Personality Questionnaire (ZKPQ). Actas Esp Psiquiatr 2007; 35:382-386. [PMID: 18004675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
INTRODUCTION The serotoninergic system seems to be implicated in characteristic symptoms of borderline personality disorder (BPD) such as affective instability, impulsivity or suicide. Some studies suggest an association between serotonin transporter gene (5-HTT) polymorphisms and some BPD symptoms. Short allele (S) of the 5-HTTLPR polymorphism in the promoter region has been shown to be associated with impulsivity, aggressive behavior, anxiety and neuroticism. Of the variable number of tandem repeat (VNTR) polymorphism in intron 2, BPD patients showed higher frequencies of the allele with the 10 repeats. The aim of this study was to determine the association between 5- HTTLPR and VNTR polymorphism of 5-HTT and personality traits in borderline personality disorder. METHOD A total of 65 BPD patients diagnosed by means of semi-structured interviews SCID-II and DIB-R were included. Two common polymorphisms of 5-HTT were genotyped: the 5-HTTLPR in the promoter region and VNTR in intron 2. Personality traits were assessed by the Zuckerman-Kuhlman Personality Questionnaire (ZKPQ). RESULTS Patients with L allele (L/S or L/L) in the 5-HTTLPR polymorphism showed lower scores on the subscale of liking parties and friends. Patients with the allele with 10 repeat of the VNTR polymorphism, showed lower scores in impulsivity, sensation seeking and in the subscale liking of parties and friends. CONCLUSIONS The results suggest a significant association between the 5-HTT gene and some personality traits in BPD. This gene may play a role in the etiology of borderline personality disorder.
Collapse
Affiliation(s)
- J C Pascual
- Psychiatry Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona , Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Vencesla A, Barcelo MJ, Baena M, Quintana M, Baiget M, Tizzano EF. Marker and real-time quantitative analyses to confirm hemophilia B carrier diagnosis of a complete deletion of the F9 gene. Haematologica 2007; 92:1583-4. [DOI: 10.3324/haematol.10693] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
35
|
Crescenti A, Mas S, Gassó P, Baiget M, Bernardo M, Lafuente A. SIMULTANEOUS GENOTYPING OF CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS IN A SPANISH POPULATION THROUGH MULTIPLEX LONG POLYMERASE CHAIN REACTION AND MINISEQUENCING MULTIPLEX SINGLE BASE EXTENSION ANALYSIS. Clin Exp Pharmacol Physiol 2007; 34:992-7. [PMID: 17714084 DOI: 10.1111/j.1440-1681.2007.04665.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
1. The aim of the present study was to perform a descriptive study of the prevalence of the four major CYP2D6 poor metaboliser (PM) alleles (*3, *4, *5 and *6) in a Spanish population (n = 290) using a method based on a new combination of multiplex long polymerase chain reaction (PCR) and minisequencing through multiplex single base extension (SBE) analysis. 2. The method was validated using different strategies, such as allelic discrimination assay and PCR-restriction fragment length polymorphism (RFLP). 3. The allele frequencies were similar to those described for other Spanish populations, namely 0.9% (95% confidence interval (CI) 0.5-1.3), 16.4% (95% CI 14.9-18.0), 2.7% (95% CI 2.0-3.4) and 0.7% (95% CI 0.3-1.0) for the *3, *4, *5 and *6 alleles, respectively. The results were satisfactory and left little doubt as to the genotypes, which were confirmed either by allelic discrimination assay (*4 and *6) or PCR-RFLP (*3) with 100% concordance. 4. The present study corroborates the low prevalence of the most frequent polymorphism (CYP2D6*4) that leads to null CYP2D6 activity in Spain and the allelic geographical gradient between Caucasian populations in the north and south. The present study reports a technique for the detection of four polymorphisms that account for 98% of the CYP2D6 defect alleles. This multiplex long PCR-SBE technique is a combination of several known methods to genotype CYP2D6 alleles (*3, *4, *5 and*6). Given the importance of CYP2D6 in drug metabolism and the need to genotype a large number of samples, we believe that this method will find broad application.
Collapse
Affiliation(s)
- A Crescenti
- Department of Pharmacology, School of Medicine, IDIBAPS, University of Barcelona, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
36
|
Paré L, Marcuello E, Altés A, del Rio E, Sedano L, Barnadas A, Baiget M. Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin? Pharmacogenomics J 2007; 8:315-20. [PMID: 17684476 DOI: 10.1038/sj.tpj.6500469] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The identification of clinical and genetic parameters to predict the outcome in advanced colorectal cancer is a key issue in the management of this disease. We ascertained whether the clinical determinants of survival defined in a large cohort of patients treated with 5-fluorouracil (5-FU) (European Organization for the Research and Treatment of Cancer, EORTC model) also apply to 109 colorectal cancer patients receiving a therapy including oxaliplatin/5-FU as their first-line treatment. Our results confirm the considerable discriminatory power of the clinical model proposed in patients treated with a combined chemotherapy regimen. With the aim of identifying additional genetic prognostic parameters, we determined whether the polymorphisms in the promoter region of the thymidylate synthase (TS) gene that modifies the number of operative binding sites of a transcription factor (USF) could predict the clinical outcome of our patients and complement the EORTC clinical model. Our results indicate that this new genetic parameter (the number of USF-binding sites) could be considered when evaluating the role of TS genotype in the efficacy of the 5-FU-based regimens. Further, confirmatory studies aimed at evaluating the effect of the number of binding sites of transcription factors for selecting 5-FU-treated patients are warranted.
Collapse
Affiliation(s)
- L Paré
- Department of Genetics, Hospital de Santa Creu i Sant Pau. Universitat Autonoma de Barcelona, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
37
|
Marcuello E, Pare L, Altes A, Rio ED, Sedano L, Barnadas A, Baiget M. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving 5-fluorouracil (FU)/oxaliplatin (OX) as first-line chemotherapy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2509 Background: Chemotherapy using oxaliplatin, 5-fluorouracil is known to be effective in the treatment of CRC patients. Optimization of this therapy is complicated due to wide variability in drug response that may be due to functional genomic polymorphisms in genes related to the drug target, to the metabolizing or to the DNA repair. We report the evaluation of polymorphisms in the TS, MTHFR (drug target) ERCC1, XPD and GSTP1 (repair enzymes) genes. Methods: We treated 109 CRC patients with a first line oxaliplatin/5-FU chemotherapeutic regimen. Genetic polymorphisms were determined by PCR based RFLP or by Real-Time PCR on an ABI PRISM 7000, using DNA from peripheral blood. The investigated polymorphisms were: TS (VNTR in the 5’ UTR, the 3R G>C SNP and the 1494del6), ERCC1 (Asn118Asn, 8092C>A, 19716 G>C), GSTP1 (Ile105Val) and XPD (Lys751Gln). Clinical response (CR), progression free survival (PFS) and overall survival (OS) were evaluated according to each genotype. Results: The patients were classified according to the clinical risk assessment (CRA) defined by EORTC in three groups with different DFS (12, 9, 7 months; P= 0.008) and different OS (41,19,11 months; P= 0.0002). In the univariate analysis for CR, ERCC1 and XPD polymorphisms were significant (P=0.03, P= 0.047, respectively). After adjustment for the mentioned clinical risk assessment, only ERCC1 retained significance (P=0.037; HR: 4.2, C/C vs T/T). In the univariate analysis for PFS, only ERCC1 polymorphism was significant (P=0.034). After adjustment for the clinical risk, this genotype did not retained its significance (P=0.37). Finally, TS, ERCC1 and XPD polymorphisms were significant in the univariate analysis for overall survival, (P=0.032, P=0.003, P=0.016 respectively). Following the adjustement for the clinical risk, all three genotype variables retained significance (P=0.019, P=0.002, P= 0.024, respectively). Conclusions: i) The EORTC risk assessment classification was a very useful predictor of DFS and OS in our group of patients; ii) Germline genetic polymorphism of ERCC1 predicted response to FU/OX in CRC patients and iii) Polymorphisms in the TS, ERCC1 and XPD genes were good predictors of overall survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - L. Pare
- Hospital Sant Pau, Barcelona, Spain
| | - A. Altes
- Hospital Sant Pau, Barcelona, Spain
| | | | | | | | | |
Collapse
|
38
|
Jaijo T, Aller E, Beneyto M, Najera C, Graziano C, Turchetti D, Seri M, Ayuso C, Baiget M, Moreno F, Morera C, Perez-Garrigues H, Millan JM. MYO7A mutation screening in Usher syndrome type I patients from diverse origins. J Med Genet 2007; 44:e71. [PMID: 17361009 PMCID: PMC2598023 DOI: 10.1136/jmg.2006.045377] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- T Jaijo
- Unidad de Genetica, Hospital Universitario La Fe, Valencia, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Badell I, del Río E, Pardo N, Farré R, Torrent M, Fraga G, Brió S, Pineda B, Baiget M, Cubells J. Aplicación de la farmacogenética a la individualización terapéutica en la leucemia linfoblástica aguda: presentación de caso clínico. An Pediatr (Barc) 2007. [DOI: 10.1016/s1695-4033(07)70454-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
40
|
Badell I, del Río E, Baiget M, Estella J, Fernández-Delgado R, Javier G, Verdeguer A, Bureo E, Couselo J, García-Miguel P, Gómez P, Indiano J, López-Ibor B, Melo M, Molina J, Moreno M, Muñoz A, Navajas A, Cubells J. Toxicidad en el tratamiento de mantenimiento del protocolo LAL/SHOP-2005. Estudio farmacogenético preliminar. An Pediatr (Barc) 2007. [DOI: 10.1016/s1695-4033(07)70465-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
41
|
Villaverde-Montero C, García-Hoyos M, Giménez-Pardo A, Trujillo-Tiebas MJ, Baiget M, Ayuso C. Gene symbol: RP2. Hum Genet 2007; 121:289. [PMID: 17598203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
|
42
|
Aller E, Jaijo T, Beneyto M, Nájera C, Oltra S, Ayuso C, Baiget M, Carballo M, Antiñolo G, Valverde D, Moreno F, Vilela C, Collado D, Pérez-Garrigues H, Navea A, Millán JM. Identification of 14 novel mutations in the long isoform of USH2A in Spanish patients with Usher syndrome type II. J Med Genet 2006; 43:e55. [PMID: 17085681 PMCID: PMC2563181 DOI: 10.1136/jmg.2006.041764] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Mutations in USH2A gene have been shown to be responsible for Usher syndrome type II, an autosomal recessive disorder characterised by hearing loss and retinitis pigmentosa. USH2A was firstly described as consisting of 21 exons, but 52 novel exons at the 3' end of the gene were recently identified. In this report, a mutation analysis of the new 52 exons of USH2A gene was carried out in 32 unrelated patients in which both disease-causing mutations could not be found after the screening of the first 21 exons of the USH2A gene. On analysing the new 52 exons, fourteen novel mutations were identified in 14 out of the 32 cases studied, including 7 missense, 5 frameshift, 1 duplication and a putative splice-site mutation.
Collapse
Affiliation(s)
- E Aller
- Unit of Genetics, Hospital La Fe, Avda Campanar, 21, 46009 Valencia, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Corominas H, Fíguls R, Riera M, Baiget M. [Phenotype of ulcerative colitis, rheumatoid arthritis, and interleukin-10 gene polymorphism]. Rev Esp Enferm Dig 2006; 98:704-5. [PMID: 17092205 DOI: 10.4321/s1130-01082006000900012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
|
44
|
Abstract
3075 Background: Pharmacogenetic determinants of the disposition of the topoisomerase I (TOP1) poison, irinotecan, appear to predict patient (pt) risk of developing severe toxicity, but do not explain all reported cases of toxicity or tumor response to irinotecan treatment. Proteins encoded by the TOP1, ADPRT, TDP1, CDC45L, NFKB1 and XRCC1 genes abate the cytotoxic action of camptothecins in vitro. Methods: Genetic variation in the drug target, TOP1, and downstream effectors may influence pt outcomes to irinotecan therapy. A retrospective haplotype-association study was undertaken to investigate the hypothesis. The association between common haplotypes of the 6 candidate genes and severe adverse events (Grade 3/4 diarrhea, neutropenia) and tumor response (objective response, overall survival) was examined in 107 advanced colorectal cancer pts treated with irinotecan-based regimens. Haplotype tags (htSNPs) were selected from haplotype cladograms of each gene. Patient DNA was typed for htSNPs using pyrosequencing and haplotype identities estimated using PHASE v.0.9. Results: Genotype frequencies were in Hardy-Weinberg equilibrium. TOP1 IVS4+61 was related to neutropenia incidence (GG<AG<AA, p<0.05) and TDP1 IVS12+79 to objective response (TT<TG<GG, p<0.05). TOP1 IVS4+61 AG+GG survived longer (24.9 months) than AA pts (7.8 months; p<0.005) and ADPRT +852 (A284A) CT+TT pts longer than CCs (p<0.05). More pts with the XRCC1 3/3 diplotype (83%) had an objective response to therapy than pts with other diplotypes (30%, p<0.05). There was a trend towards more ADPRT 2/2s (33%) experiencing severe neutropenia than pts with other diplotypes (13%, p=0.08). No genetic variant influenced diarrhea incidence. Conclusions: This is the first pharmacogenetic investigation of irinotecan pharmacodynamic factors. Our results suggest TOP1 and ADPRT variants may alter a patient’s risk of experiencing neutropenia and TOP1, TDP1, ADPRT and XRCC1 variants may influence tumor response to irinotecan-based therapies. [Table: see text]
Collapse
Affiliation(s)
- J. M. Hoskins
- Washington University, St. Louis, MO; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M. Baiget
- Washington University, St. Louis, MO; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - E. Marcuello
- Washington University, St. Louis, MO; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - A. Altes
- Washington University, St. Louis, MO; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - H. L. McLeod
- Washington University, St. Louis, MO; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| |
Collapse
|
45
|
Bach V, Barceló MJ, Altés A, Remacha A, Félez J, Baiget M. Genotyping the HFE gene by melting point analysis with the LightCycler system: Pros and cons. Blood Cells Mol Dis 2006; 36:288-91. [PMID: 16515868 DOI: 10.1016/j.bcmd.2005.12.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2005] [Revised: 12/09/2005] [Accepted: 12/19/2005] [Indexed: 11/19/2022]
Abstract
The assay that combines rapid-cycle PCR with allele-specific fluorescent probe melting profiles performed on the Roche Diagnostics LightCycler is commonly employed for genotyping the HFE gene. We report three illustrative cases of the pros and cons of this method. In two cases, atypical melting curves allows the identification of new DNA substitutions in the HFE gene, whereas, in the third case, a typical melting curve of c.845G>A mutation (C282Y) homozygosity overlooks a nucleotide change and promotes misdiagnosis of HH.
Collapse
Affiliation(s)
- V Bach
- Servei de Genètica, Hospital de Sant Pau, Avda. Pare Claret 167, 08025 Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
46
|
Jaijo T, Aller E, Oltra S, Beneyto M, Nájera C, Ayuso C, Baiget M, Carballo M, Antiñolo G, Valverde D, Moreno F, Vilela C, Perez-Garrigues H, Navea A, Millán JM. Mutation profile of the MYO7A gene in Spanish patients with Usher syndrome type I. Hum Mutat 2006; 27:290-1. [PMID: 16470552 DOI: 10.1002/humu.9404] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Usher syndrome type I is the most severe form of Usher syndrome. It is an autosomal recessive disorder characterized by profound congenital sensorineural deafness, retinitis pigmentosa, and vestibular abnormalities. Mutations in the myosin VIIA gene (MYO7A) are responsible for Usher syndrome type 1B (USH1B). This gene is thought to bear greatest responsibility for USH1 and, depending on the study, has been reported to account for between 24% and 59% of USH1 cases. In this report a mutation screening of the MYO7A gene was carried out in a series of 48 unrelated USH1 families using single strand conformation polymorphism analysis (SSCP) and direct sequencing of those fragments showed an abnormal electrophoretic pattern. Twenty-five mutations were identified in 23 out of the 48 families studied (47.9%). Twelve of these mutations were novel, including five missense mutations, three premature stop codons, three frameshift, and one putative splice-site mutation. Based on our results we can conclude there is an absence of hot spot mutations in the MYO7A gene and that this gene plays a major role in Usher syndrome.
Collapse
Affiliation(s)
- T Jaijo
- Unidad de Genética, Hospital La Fe, Valencia, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Bach V, Remacha A, Altés A, Barceló MJ, Molina MA, Baiget M. Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. Blood Cells Mol Dis 2005; 36:41-5. [PMID: 16257244 DOI: 10.1016/j.bcmd.2005.09.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2005] [Revised: 09/22/2005] [Accepted: 09/22/2005] [Indexed: 01/01/2023]
Abstract
Hereditary hemochromatosis is a common disorder of iron metabolism most frequently associated with mutations in the HFE gene. Hereditary hemochromatosis may be caused by other genetic mutations including those in the SLC40A1 gene. This report describes the clinical and laboratory findings of two Spanish families with autosomal dominant iron overload associated with previously unrecognized Ferroportin 1 mutations (p.R88T and p.I180T). The phenotype of iron overload in the patients carrying these mutations could correspond to the group of clinical mutations that lose their iron export function.
Collapse
Affiliation(s)
- V Bach
- Servei de Genètica. Hospital de Sant Pau, Avda. Pare Claret 167. 08025 Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
48
|
Bernal S, Medà C, Solans T, Ayuso C, Garcia-Sandoval B, Valverde D, Del Rio E, Baiget M. Clinical and genetic studies in Spanish patients with Usher syndrome type II: description of new mutations and evidence for a lack of genotype--phenotype correlation. Clin Genet 2005; 68:204-14. [PMID: 16098008 DOI: 10.1111/j.1399-0004.2005.00481.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Patients with Usher syndrome type II (USH2) show moderate-to-severe hearing loss (HL), retinitis pigmentosa and normal vestibular function. The progression of HL remains controversial. To evaluate whether a phenotype-genotype correlation exists regarding the issue of progression of HL, only USH2 patients with a defined genotype were selected. Ophthalmologic, vestibular and audiometric examination along with a mutation analysis of the USH2A gene (exons 1--21) was performed in twenty-eight Spanish USH2 patients. Ten different pathogenic mutations and 17 sequence variants not associated with the disease were found. Six of the 10 mutations are novel. Disease alleles were identified in 13 of the 28 families tested. Eight of these 13 families had a mutation found in both alleles. In the other five families, only one mutation was identified. The phenotypic data provide evidence for the existence of phenotypic differences between patients with the same genotype. These differences were observed at both the interfamilial and intrafamilial levels.
Collapse
Affiliation(s)
- S Bernal
- Servei de Genètica, Universidad de Vigo, Vigo, Spain
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Marcuello E, Altés A, Menoyo A, Rio ED, Baiget M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2005; 57:835-40. [PMID: 16187112 DOI: 10.1007/s00280-005-0089-1] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2005] [Accepted: 07/25/2005] [Indexed: 01/02/2023]
Abstract
Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) may play a central role in the action of 5-FU, an inhibitor of thymidylate synthase, by converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. The aim of this study was to ascertain whether two polymorphisms in the MTHFR gene (677C>T and 1298 A>C) could be used as genomic predictors of clinical response to fluoropyrimidine-based chemotherapy (in combination with irinotecan or oxaliplatin). Ninety-four patients diagnosed with metastatic colorectal cancer and undergoing 5-FU-containing chemotherapy as a first line treatment were studied. The results suggest that the MTHFR genotype cannot be considered as an independent factor of outcome in colorectal cancer patients under 5-FU-based chemotherapy.
Collapse
Affiliation(s)
- E Marcuello
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Avda. S. Antoni M. Claret 167, 08025, Barcelona, Spain
| | | | | | | | | |
Collapse
|
50
|
Cuscó I, Barceló MJ, Rojas-García R, Illa I, Gámez J, Cervera C, Pou A, Izquierdo G, Baiget M, Tizzano EF. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol 2005; 253:21-5. [PMID: 15981080 DOI: 10.1007/s00415-005-0912-y] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2004] [Revised: 11/22/2004] [Accepted: 02/23/2005] [Indexed: 12/21/2022]
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive disorder that affects motor neurons. It is caused by mutations in the survival motor neuron gene 1 (SMN1). The SMN2 gene, which is the highly homologous SMN1 copy that is present in all the patients, is unable to prevent the disease. An SMN2 dosage method was applied to 45 patients with the three SMA types (I-III) and to four pairs of siblings with chronic SMA (II-III) and different phenotypes. Our results confirm that the SMN2 copy number plays a key role in predicting acute or chronic SMA. However, siblings with different SMA phenotypes show an identical SMN2 copy number and identical markers, indicating that the genetic background around the SMA locus is insufficient to account for the intrafamilial variability. In our results, age of onset appears to be the most important predictor of disease severity in affected members of the same family. Given that SMN2 is regarded as a target for potential pharmacological therapies in SMA, the identification of genetic factors other than the SMN genes is necessary to better understand the pathogenesis of the disease in order to implement additional therapeutic approaches.
Collapse
Affiliation(s)
- I Cuscó
- Dept. of Genetics and Research Institute, Hospital de Sant Pau, Av. Padre Claret 167, 08025, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|